IMMX: Bathi resik saben saham (EPS TTM) Immix

Immix Biopharma, Inc. (IMMX) operates as a flexible scientific hub, outsourcing production and testing to external partners. The current EPS TTM historical trend on the GURU.Markets chart shows that the current value is -0.83. A critical dependence on third-party contractors and the early stages of cancer therapy development create negative operating leverage, increasing per-unit R&D costs.

Net income per share measures the owner's stake in the final annual financial result. By analyzing this annual net income per share chart, an investor assesses the efficiency of capital generation relative to the total shares outstanding. The metric is calculated by dividing the total income over 12 months by the total number of shares. For Immix Biopharma, Inc. (IMMX), negative values reflect the costs of the large-scale deployment of CAR-T therapy clinical trials. This confirms a stage of active investment in cell modification to secure future approvals.